A Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of AXL Inhibitor FC084CSA Tablets in Combination With Tislelizumab in the Treatment of Advanced Malignant Solid Tumors

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FC 084CSA (Primary) ; Tislelizumab (Primary)
Indications Solid tumours
Focus Adverse reactions; Therapeutic Use

Most Recent Events

21 Oct 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
16 Oct 2024 Planned initiation date changed from 10 Sep 2024 to 10 Nov 2024.
18 Jul 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight